This is my story.
I have always been drawn to complex systems. From designing and testing machinery in power generation and oil and gas, to omics research in biomedicine and data-driven analysis in finance, the common thread has been the search for hidden structure, signal extraction, and optimization paths. I build tools that turn complex data into actionable decisions, whether the outcome is improved efficiency, better diagnostics, or refined performance. The domain changes, but the process remains the same: understanding the system, defining the right metrics, and translating uncertainty into insight. For me, the subject matter is secondary. What drives my work is advancing knowledge within any system by combining engineering rigor, analytical thinking, and continuous learning.
I am an engineer and biomedical researcher working at the intersection of engineering, data science, and translational research. My academic path reflects a commitment to continuous learning, with three engineering degrees followed by a PhD in Biomedicine, currently in its final stage. In industry, I contributed to the design, testing, and delivery of power and distribution transformers at Siemens, and later developed custom topside equipment for oil and gas projects, balancing client-specific requirements with engineering rigor. In parallel, I founded and led my own company, an entrepreneurial effort that continues today in research-driven innovation, with a patent in progress focused on biomarker-based diagnostics and prognosis for complex diseases. Since completing my Master’s in Biomedical Engineering, my work has centered on omics-driven biomarker discovery, machine learning, and statistical pipelines that translate complex biological data into actionable insights. I am motivated by projects where systems thinking, computation, and experimentation converge to generate measurable impact.
I have extensive experience across biomedical research, data analytics, and engineering, with a strong focus on building quantitative pipelines that support interpretation, prediction, and decision-making in complex systems. In research, I have designed and implemented biomarker discovery and machine learning workflows for omics studies, including metabolomics and proteomics, supporting diagnostic and prognostic modeling in critical care and complex disease contexts. These pipelines integrate data preprocessing, feature selection, statistical analysis, and supervised and unsupervised learning, with an emphasis on robustness and interpretability. My work is supported by a strong computational foundation, using Python, statistical tools, and data mining platforms, alongside ETL processes, visualization, and reporting. I also extend these skills to database-driven and analytics environments, including SQL-based systems and cloud deployments. My engineering background provides additional depth in system modeling, simulation, and validation, including mechanical design, numerical analysis, and physical system integration. This cross-domain perspective allows me to bridge experimental data, computational models, and real-world constraints, with a consistent focus on reproducibility, scalability, and continuous improvement.
My extensive professional background and educational qualifications.
Apr 2020 – Oct 2020
Jan 2020 – Apr 2020
Oct 2017 – Apr 2018
Oct 2016 – Oct 2017
Sep 2014 – Jun 2015
Aug 2012 – Aug 2014
Jun 2011 – Jun 2012
Fev 2010 – Jul 2010
2008 – Seasonal
November 2021 – November 2025
October 2017 – December 2019
October 2007 – February 2011
October 2002 – July 2007
Nov 2021 – Present
Oct 2017 – Present
Jun 2011 – Jun 2015
Integrated in various research groups. For example, the development of new corrogated pannels for ATEX Large Distribution Transformers (mechanical + finite elements + thermodynamics analysis), and novel custom and client-oriented engineering designs for the oil and gas industry (topside equipment - Vertical Pipe Handling and Drilling & Make/Break equipment).
2017 – 2020
2017 – 2020
2020
2012-2013
2009
2009
2008
ongoing (self-study)
ongoing (self-study)
A list of my academic contributions.
It is relevant to discover biomarkers enabling to predict critically ill patients’ survival. This study focused on 45 patients, from which 22 deceased and 23 were discharged from an Intensive Care Unit (ICU). It was considered the serum molecular fingerprint, as acquired by Fourier Transform Infra-Red (FTIR) spectroscopy, obtained 3 days before the patients discharged or death at the ICU. It was possible to obtain ratios of bands of the sera spectra, statistically different between the two groups of patients. Furthermore, good Naïve Bayes models were developed based on the second derivative spectra enabling an Area Under the Receiver Operating Characteristic Curve (AUC-ROC) of 0.77. These promising outputs suggest further investigation with a larger cohort.
INTENSIVE CARE UNIT, SURVIVAL, BIOMARKERS
It is relevant to discover infection biomarkers, especially for critically ill patients in intensive care units (ICU), as these patients often present non-infectious inflammatory processes that obscure typical infectious markers. This study focused on 20 ICU patients, half of whom had acquired bacterial blood infections (bacteremia). Due to the significance of inflammatory processes in these patients, it was evaluated how 21 serum cytokines could be used to develop predictive models for bacteremia. Feature selection using a Gain Information algorithm allowed for the construction of an excellent Naïve Bayes model, achieving an AUC of 0.950. These promising results strongly support future studies with larger cohorts, to further evaluate these types of platforms for infection diagnosis in such critical populations.
INFECTION BIOMARKERS, INTENSIVE CARE UNIT, CYTOKINES
Omics Sciences serve as an essential tool to advance precision medicine. Since conventional omics sciences rely on laborious, complex and time-consuming analytical processes, this study evaluated whether the serum molecular fingerprint, captured by FTIR spectroscopy, could predict mortality risk in critically ill patients. Both the whole serum and the serum metabolome (i.e., serum after removal of macromolecules) were analyzed. PCA-LDA models demonstrated strong performance in predicting patients’ pathophysiological state. A significantly more accurate model for predicting the patients’ pathophysiological state was achieved using the serum metabolome (94%) compared to the whole serum (81%). This is consistent with metabolomics, which provides a more direct view of the systems’ functionality. These promising results highlight the importance of FTIR spectroscopy analysis of the serum metabolome, offering a rapid, cost-effective, and high-throughput method for assessing patients' pathophysiological state.
BIOMARKERS, FTIR SPECTROSCOPY, METABOLOME, INTENSIVE CARE UNIT
As SARS-CoV-2 continues to circulate globally and new variants emerge, it remains relevant to gather data on the affected patients’ clinical characteristics and outcomes to understand how individual factors and public health measures affect prognosis. Thus, we analyzed data of 870 ICU patients admitted for COVID-19 across two distinct phases of the pandemic: before and after the introduction of immunization. Experimental results showed that vaccination significantly impacted patient demographics after the third wave, and that waves number two and three, dominated by the EU1 and Alpha variants, had higher mortality. Older age, the need for invasive mechanical ventilation, and hematologic cancer were significantly associated with an increased risk of death in the adjusted multivariable model (AUC: 0.778, 95% CI 0.746-0.810, p<0.001). As the pandemic progressed, while some public health interventions influenced the observed trends, individual patient characteristics had a more substantial impact on their outcome.
COVID-19 WAVES, COVID-19 VACCINATION, INTENSIVE CARE UNIT, MORTALITY
The available scores to predict patients’ outcomes in specific settings generally present low sensitivities and specificities when applied to intensive care units’ (ICUs) populations. Advancements in analytical techniques, notably Ultra-High Performance Liquid Chromatography- Mass Spectrometry (UHPLC-HRMS) transformed biomarker identification, enabling a comprehensive profiling of biofluids, including serum. In the current work, untargeted metabolomics, utilizing UHPLC-HRMS serum analysis, was performed on 16 ICU patients, categorized as either discharged (n=8), or deceased (n=8) in average seven days post sample collection. Linear discriminant analysis (LDA) or principal component analysis (PCA)-LDA models involving different metabolite sets were developed, enabling to predict patients’ outcomes in the ICU with 92% accuracy and 83% sensitivity on validation datasets. These results highlight the advantages of UHPLC-HRMS as a platform capable of providing a set of clinically significant biomarkers to predict patients’ outcome.
BIOMARKERS, INTENSIVE CARE UNIT, PREDICTIVE MODELS, METABOLOMICS, MASS SPECTROMETRY
Highly sensitized patients have very limited access to kidney transplantation, resulting in a long waiting time on dialysis. Delisting of prohibited HLA antigens should allow the performance of DSA-positive, crossmatch-negative transplants. We describe the experience of four Spanish transplant centers after delisting prohibited HLA antigens to reduce cPRA below 99%. Delisting was gradually performed, allowing HLA antigens with MFI < 5000, avoiding repeated antigens from previous transplants. If the cPRA did not decrease, a more aggressive HLA delisting was performed up to a maximum MFI of 10,000 except for DP. In some cases, the capacity to activate complement (C3d or C1q) and the 1/16 dilution were performed to individually decide the delisting. Forty-eight patients underwent delisting from May 2022 to August 2023, with total time on the waiting list of 5.6 [3.3–9.1] years and time on dialysis of 9.8 [5.7–13.5] years. Baseline cPRA was 100.0 [99.9–100.0]%. After delisting, it dropped to 98.3 [96.0–99.0]%. Thirty patients obtained an offer within the Spanish Highly Sensitized Program (PATHI) after a period of 98 [52–154] days of which 18 had a negative CDC and flow cytometry crossmatch and underwent kidney transplant. The number of DSAs at the time of transplant was 2 [1–4], with MFI of the dominant DSA of 8036 [3857–20,951]. 55.6% of recipients received post-transplant desensitization. Rejection developed in 7 patients (38.9%), in all cases humoral and in 2 cases (11.1%) mixed, after 43 [13–91] days post-transplant. In only two cases rejection could not be controlled with treatment and, in one case, it progressed to chronic antibody-mediated rejection. All grafts, except one, are functional at 186 [67–384] days post-transplant and, in 7 patients, at 1 year of follow-up. A delisting strategy can be considered for hypersensitized patients who have no other options to find a compatible donor on the waiting list.
The aim of this study was the estimation of the effect of long-term kidney transplantation on T and B regulatory lymphocytes. Patients who had received a transplant 17+ years ago (group A) and 1 year ago (group B) took part in the study. The subpopulations of CD4 + CD25 + FOXP3 (Tregs), CD19 + CD24++CD38++ (Bregs1), CD19 + CD27 + CD24++ (Bregs2) and naïve, switched, non-switched memory and double negative (DN) B-lymphocytes were measured by flow cytometry. Patients of group A (N = 20, M/F = 11/9) did not differ with patients of group B (N = 40, M/F = 23/17) regarding age (57 vs 56 years, p = 0.065) and eGFR (63.5 ± 19.2 vs 63.6 ± 17, 1 mL/min/1,73 m², p = 0.132). Significant differences between groups were observed in respect of the percentage of Tregs (2.55 vs 4.7%, p < 0.001), the percentage and number of Bregs1 (1.6 vs 0.0%, p < 0.001 and 0.53 vs 0.0/μL, p = 0.001) and Bregs2 (0.0 vs 2.55%, p < 0.001 and 0.0 vs 2.0/μL, p = 0.001). Group A also exhibited a significant reduction of B-lymphocytes (55 vs 99/μL, p = 0.034), which mainly referred to naïve (18 vs 41/μL, p = 0.005), switched (7.26 vs 14/μL, p = 0.005), and non-switched memory (1.22 vs 13/μL, p < 0.001) B-cells, with a simultaneous increase of DN cells (22 vs 11/μL, p = 0.028). Long-term kidney transplant recipients show a reduction of the percentage of Tregs, a rise of Bregs1 and a decline of Bregs2 as well as significant alterations of B-lymphocyte subpopulations.
The diagnosis of infections in hospital or clinical settings usually involves a series of time-consuming steps, including biological sample collection, culture growth of the organism isolation and subsequent characterization. For this, there are diverse infection biomarkers based on blood analysis, however, these are of limited use in patients presenting confound processes as inflammatory process as occurring at intensive care units. In this preliminary study, the application of serum analysis by FTIR spectroscopy, to predict bacteraemia in 102 critically ill patients in an ICU was evaluated. It was analysed the effect of spectra pre-processing methods and spectral sub-regions on t-distributed stochastic neighbour embedding. By optimizing Support Vector Machine (SVM) models, based on normalised second derivative spectra of a smaller subregion, it was possible to achieve a good bacteraemia predictive model with a sensitivity and specificity of 76%. Since FTIR spectra of serum is acquired in a simple, economic and rapid mode, the technique presents the potential to be a cost-effective methodology of bacteraemia identification, with special relevance in critically ill patients, where a rapid infection diagnostic will allow to avoid the unnecessary use of antibiotics, which ultimately will ease the load on already fragile patients' metabolism.
FTIR SPECTROSCOPY, INFECTION, BIOMARKERS, INTENSIVE CARE UNIT
Besides the pandemic being over, new SARS-CoV-2 lineages, and sub-lineages, still pose risks to global health. Thus, in this preliminary study, to better understand the characteristics of COVID-19 patients and the effect of certain hematologic biomarkers on their outcome, we analyzed data from 337 patients admitted to the ICU of a single-center hospital in Lisbon, Portugal, in the first three waves of the pandemic. Most patients belonged to the second (40.4%) and third (41.2%) waves. The ones from the first wave were significantly older and relied more on respiratory techniques like invasive mechanic ventilation and extracorporeal membrane oxygenation. There were no significant differences between waves regarding mortality in the ICU. In general, non-survivors had worse laboratory results. Biomarkers significantly associated with death changed depending on the waves. Increased high-sensitivity cardiac troponin I results, and lower eosinophil counts were associated to death in all waves. In the second and third waves, the international normalized ratio, lymphocyte counts, and neutrophil counts were also associated to mortality. A higher risk of death was linked to increased myoglobin results in the first two waves, as well as increased creatine kinase results, and lower platelet counts in the third wave.
COVID-19, WAVES, BIOMARKERS, ICU, RISK OF DEATH
Metabolomics has emerged as a powerful tool in the discovery of new biomarkers for medical diagnosis and prognosis. However, there are numerous challenges, such as the methods used to characterize the system metabolome. In the present work, the comparison of two analytical platforms to acquire the serum metabolome of critically ill patients was conducted. The untargeted serum metabolome analysis by ultraperformance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) enabled to identify a set of metabolites statistically different between deceased and discharged patients. This set of metabolites also enabled to develop a very good predictive model, based on linear discriminant analysis (LDA) with a sensitivity and specificity of 80% and 100%, respectively. Fourier Transform Infrared (FTIR) spectroscopy was also applied in a high-throughput, simple and rapid mode to analyze the serum metabolome. Despite this technique not enabling the identification of metabolites, it allowed to identify molecular fingerprints associated to each patient group, while leading to a good predictive model, based on principal component analysis-LDA, with a sensitivity and specificity of 100% and 90%, respectively. Therefore, both analytical techniques presented complementary characteristics, that should be further explored for metabolome characterization and application as for biomarkers discovery for medical diagnosis and prognosis.
METABOLOMICS, MASS SPECTROMETRY, LIQUID CHROMATOGRAPHY, FOURIER TRANSFORM INFRARED SPECTROSCOPY
Epigallocatechin-3-gallate (EGCG), the major catechin present in green tea, displays diverse biological activities as anti-oxidation, anti-inflammation, anti-proliferation and anti-microbial among others. In the present work it was evaluated the effect of the consumption of EGCG along 90 days on healthy human volunteers (n=30) on plasma molecular signature acquired by mid-infrared (MIR) spectroscopy. It was observed by principal component analysis of spectra that plasma samples presented a significant different molecular profile after 90 days of EGCG consumption. Based on the corresponding loading vector, it was observed that EGCG consumption affected the profile of the major molecules as proteins and lipids. Were identified diverse ratios of spectral bands statistically different (p <; 0.01) after EGCG consumption, according to a high impact of EGCG on the general metabolism. MIR spectroscopy enabled to acquire the plasma whole molecular signature in a highly sensitive and specific mode. Since the MIR spectra is also acquired in an economic, simple, fast and high-throughput mode, the technique presents promising characteristics to acquire information in large-scale epidemiological studies towards a better understand of the in vivo effect of EGCG.
GREEN TEA, EPIGALLOCATECHIN, POLYPHENOLS, METABOLOMICS
Background: Cytokine storms significantly influence systemic inflammatory responses and septic patient outcome, highlighting the critical role of cytokine profiling in understanding and predicting patient’s outcome [1], which holds significant potential for future clinical and therapeutic applications. The present work aims to evaluate how serum cytokines can predict the outcome of septic patients at intensive care units (ICU). Methods: Serum samples from 16 septic patients (7 discharged, 9 deceased) were analyzed using a Milliplex 384-Well High Sensitivity Human T Cell Magnetic Bead Panel to profile a comprehensive set of 21 cytokines: ITAC, GM-CSF, Fractalkine, IFN-g, IL-10, MIP-3a, IL-12p70, IL-13, IL-17a, IL-1b, IL-2, IL-21, IL-4, IL-23, IL-5, IL-6, IL-7, IL-8, MIP-1a, MIP-1b, and TNF-a. Machine learning tools coupled to a Gini decrease ranking method were employed to identify cytokines critical for discriminating between deceased and discharged patients. Results: Preliminary findings indicate that IL-6, MIP-3a, IL-8, IL-12p70, and IL-10 are notably linked to sepsis outcomes. The relevance of these cytokines aligns with existing literature on their roles in inflammation and immune responses [2]. Predictive models constructed using the Naive Bayes models showed promising results, with sensitivity and specificity exceeding 86%. Conclusion: This study underscores the importance of cytokine profiling in sepsis, highlighting key biomarkers for predicting patient outcomes.
SEPSIS, SERUM CYTOKINES, BIOMARKERS, ICU MORTALITY
In a hospital setting, diagnosing infections typically involves a complex process that includes the collection of biological samples and growing a culture for organism isolation, followed by its characterization. However, these methods are slow, require multiple steps and are often limited by the need of specialized equipment and skilled personnel. In this preliminary study, it was analysed the serum, by FTIR spectroscopy, of 29 critically ill COVID-19 patients in an ICU. It was analysed the effect of varied pre-processing methods and spectral sub-regions on t-SNE. Through the optimization of SVM models, it was possible to achieve a very good gram predictive model with a sensitivity and specificity of 90 and 89% respectively. As an accurate classification of bacterial strains is crucial to guide effective antimicrobial therapy and prevent the spread of multidrug-resistant bacteria, FTIR spectra, acquired in a simple, economic, and rapid mode, presents therefore the potential for development of new classification methods that would greatly enhance the ability to manage bacterial infections.
Due to the relevance of mortality prediction of critically ill patients, it is common practice at intensive care units (ICU) to use physiological scores, e.g., APACHE II. However, these type of scorings don’t enable to predict individual patients’ outcome, mostly used for comparing groups of patients and ICUs [1]. It is therefore relevant to discover robust biomarkers of mortality prediction at ICU. Since FTIR spectroscopy can capture the whole molecular fingerprint of a system in a very specific and sensitive mode [2,3], in the present work, diverse mortality predictive models of support vector machines (SVM), based on FTIR-spectra of serum of critically ill patients, were developed. Serum samples from 200 patients at an ICU, with half presenting COVID-19 and the other half not presenting this infection, were considered. SVM models were optimized by combining spectral regions with diverse spectra pre-processing methods. A model cross-validation strategy, based on 10 random iterations, with 80% of samples for training and 20% for validation, was implemented. It was possible to develop very good SVM models to predict mortality based only on patients without COVID-19 (AUC=0.90), and a slightly better model was achiever for patients with COVID-19 (AUC=0.93). This difference can result from COVID-19 patients presenting a different metabolic status in relation to non-COVID-19 patients. Indeed, a very good SVM model enabled to discriminate these two populations (AUC=0.83). When considering the mixed population (i.e., with and without COVID-19), a slightly worse predictive SVM model was obtained (AUC=0.88).
FTIR, COVID-19, MORTALITY, ICU, BIOMARKERS
Metabolomics has emerged as a powerful tool in the discovery of new biomarkers for medical diagnosis and prognosis. Metabolomics of biofluids, such as serum, can therefore potentially deliver biomarkers that may be applicable in patients’ monitoring [1]. This is especially relevant in the management of critically ill patients. However, there are numerous challenges, including the metabolome isolation process and the subsequent platform applied to analyze it. FTIR-spectroscopy presents diverse advantages for metabolome analysis, since it may be applied in rapid, economic, and high-throughput mode, while enabling to acquire the system’s metabolic status with a high sensitivity and specificity [2,3]. In the current project, two extraction protocols of the serum metabolome were evaluated. Both protocols included macromolecules precipitation induced by mixtures of methanol, acetonitrile, and water. Replicas of 5L extracted serum metabolome, from critically ill patients, were plated in 384 wells-microplates, and after a rapid dehydration step, spectra were acquired between 400 to 4000 cm-1. The impact of the two extraction procedures to isolate the serum metabolome, on reproducibility, based on FTIR-spectra principal component analysis (PCA) was studied. The impact of the two extraction procedures on the performance of predictive models, based on spectra PCA-discriminant analysis of patients’ mortality, was also conducted. Serum samples from critically ill patients were obtained according to legal and ethics requirements, including project ethics approval by the Hospital Ethics Committee (Centro Hospitalar Universitário Lisboa Central), and patients’ informed consent.
The ability to measure and evaluate [1] is a major exercise in the daily lives of health professionals, regardless of their speciality, may they be physiotherapists, nurses, doctors, prosthetist and orthotisc and of biomedical engineers, who assist in the whole process of gathering the data and analysing it. This exercise must be realized in a professional, responsible and economic manner and ultimately based on backed-up evidence. Therefore it is of extreme importance to focus on a correct and accurate measurement system and be able to properly evaluate a persons’s illness or disability. To understand the results of the study case that was reviewed [2], it becomes important to understand two important and different definitions: outcome and outcome measure. A database of a few of the measures available can be consulted online. [3] [4]. An outcome is a “measurable individual, family, or community state, behavior or perception that is measured along a continuum and is responsive to clinical interventions” [5]. An outcome measure is a set of items that are used to create scores that are “intended to quantify a patient’s performance or health status based on standardized evaluation protocols or closed ended questions”. [5] It is therefore important to make sure that these patient characteristics are measured using standardized outcome instruments so that they can be adequately stored in electronic records, allowing for its use by clinical bodies, to facilitate in the identification of signal or symptoms of any healthy condition, making the diagnostic and call for action easier, all the while contributing to the development of clinical knowledge and professional education. [6] More detailed information about outcome measurements can be consulted in [7].
At the NOVA Summer Medical School: Lifestyle (Lisbon, July 3, 2025), an oral presentation addressed the role of Big Data and Artificial Intelligence in healthcare. The session introduced core concepts of machine learning, programming, and omics, highlighting their integration into diagnostics and clinical decision-making. The discussion emphasized both the transformative potential of these technologies and their relevance for driving future innovation in medical practice.
The XIV Meeting of Quality Researchers (RIQUAL), held at Instituto Superior de Engenharia de Lisboa on June 28, 2024, focused on advancing knowledge and practices in quality across diverse domains. The event covered themes such as accreditation, certification, environmental and safety management, social responsibility, sustainability, health, education, and information systems. A special session was dedicated to showcasing student research projects, dissertations, and theses aligned with these topics.
The rapid discrimination between fungal and bacterial infections in intensive care unit (ICU) patients is crucial for an efficient antimicrobial therapy. This work aims to develop a predictive model capable of discriminating fungal and bacterial infections among these patients based on a rapid serum analysis. Serum from 46 patients at ICU, with COVID-19, were analyzed by Fourier-Transform infrared (FTIR) spectroscopy: 17 did not present any other infection; 12 presented bacterial infections (including Enterobacter aerogenes (2), Escherichia coli (4), Enterococcus faecalis (1), Haemophilus influenzae (1) and Serratia marcescens (1), Klebsiella pneumoniae (3)), isolated from blood, tracheobronchial aspiration, bronchoalveolar lavage and urine; 17 with fungal infections (including Candida albicans (14), C. tropicalis (1), C. parapsilosis (1) and C. glabrata (1), isolated from bronchoalveolar lavage, urine and urethral exudate. The impact of a Fast Correlation Based Filter (FCBF) of normalized second derivatized spectra (between 406-1800 and 2800-3992 cm-1) was evaluated on a t-distributed Stochastic Neighbor Embedding (t-SNE), and a Naïve-Bayes model. The predictive models were based on 10 random iterations, with 80% of samples used for training and the remaining 20% for validation. The impact of FCBF was evaluated on t-SNE to select the spectral bands with high significance in detecting the infection and in discriminating the bacterial from the fungus infection. Optimized Naïve-Bayes models enabled to detect the infection with a sensitivity of 83% and a specificity of 81%, and the discrimination of the bacterial and fungal infection with a sensitivity and specificity of 86% and 96%, respectively. Serum analysis, based on FTIR spectroscopy associated to machine learning algorithms presents a high potential to detect in a rapid and economic mode either the infection either the discrimination between bacterial or fungal infection.
FTIR SPECTROSCOPY, INTENSIVE CARE UNIT, FUNGAL INFECTION, BACTERIAL INFECTION, DIAGNOSTICS
A display of varied engineering expertise, clinical research and finance-oriented skills.
Personal Pursuits.
© Copyright | Design by Ruben Araujo.